Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in metastatic castration-resistant prostate cancer
ACTRN12622001003763Phase 2Recruiting
- Sponsor
- National Health and Medical Research Council
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of evolocumab in prostate cancer (PCa), sponsored by National Health and Medical Research Council. Primary endpoint: Change in circulating lipid profile. Started Mar 2023; status: recruiting.
02
Drugs
evolocumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12622001003763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001003763.